ECO-BRITE 150 DETERGENT

Informasi Utama

  • Nama dagang:
  • ECO-BRITE 150 DETERGENT
  • Digunakan untuk:
  • manusia
  • Jenis Obat:
  • Perangkat medis

Dokumen

  • untuk masyarakat umum:
  • Informasi leaflet untuk produk ini saat ini tidak tersedia, Anda dapat mengirim permintaan untuk layanan pelanggan kami dan kami akan memberitahu Anda segera setelah kami mampu mendapatkannya.


    Meminta selebaran informasi untuk masyarakat umum.

Lokalisasi

  • Tersedia di:
  • ECO-BRITE 150 DETERGENT
    Indonesia
  • Bahasa:
  • Bahasa Indonesia

Informasi lainnya

Status

  • Sumber:
  • Ecolab
  • Nomor Otorisasi:
  • 913315
  • Pembaharuan Terakhir:
  • 12-03-2018

Ringkasan karakteristik Produk: dosis, interaksi, efek samping

LEMBARAN DATA KESELAMATAN BAHAN

ECO-BRITE 150 DETERGENT

913315

1 / 8

BAGIAN 1. IDENTIFIKASI SENYAWA (TUNGGAL ATAU CAMPURAN)

Nama Produk

ECO-BRITE 150 DETERGENT

Cara identifikasi lainnya

Tidak berlaku.

Penggunaan yang dianjurkan

Deterjen binatu

Pembatasan penggunaan

Disediakan untuk penggunaan industrial dan profesional.

Informasi pengenceran

produk

Produk dijual siap pakai.

Perusahaan

PT. Ecolab International Indonesia

Jl. Jababeka XII.B Kav V-37

Kawasan Industri Jababeka, Cikarang Indonesia 17530

(62-21) 8983 4891

Nomor telepon darurat

+1-651-222-5352 (Amerika Syarikat)

Tanggal penerbitan pertama

28.07.2016

BAGIAN 2. IDENTIFIKASI BAHAYA

Klasifikasi GHS

Toksisitas akut (oral)

Kategori 4

Korosi/iritasi kulit

Kategori 1

Kerusakan mata serius/iritasi

pada mata

Kategori 1

Elemen label GHS

Piktogram bahaya

Kata sinyal

Bahaya

Pernyataan Berbahaya

Berbahaya jika tertelan.

Menyebabkan kulit terbakar yang parah dan kerusakan mata.

Pernyataan Hati-hati

Pencegahan:

Jangan menghirup debu atau kabut. Cuci kulit dengan seksama

setelah menangani. Jangan makan, minum atau merokok pada saat

menggunakan produk ini. Pakai sarung tangan pelindung /pakaian

pelindung /pelindung mata/pelindung wajah.

Respons:

JIKA TERTELAN: Telponlah ke PUSAT RACUN/ dokter bila anda

merasa tidak sehat. Berkumurlah. JIKA TERTELAN : Basuh mulut.

JANGAN merangsang muntah. JIKA TERKENA KULIT (atau rambut):

Tanggalkan segera semua pakaian yang terkontaminasi. Bilas kulit

dengan air/pancuran. JIKA TERHIRUP: Pindahkan korban ke udara

segar dan posisikan yang nyaman untuk bernapas. Segera hubungi

SENTRA INFORMASI KERACUNAN atau dokter/tenaga medis. JIKA

TERKENA MATA: Bilas secara hati-hati dengan air selama beberapa

menit. Lepas lensa kontak, jika digunakan dan mudah melakukannya.

Lanjutkan membilas. Segera telponlah PUSAT RACUN atau dokter.

LEMBARAN DATA KESELAMATAN BAHAN

ECO-BRITE 150 DETERGENT

913315

2 / 8

Cucilah pakaian yang terkontaminasi sebelum digunakan kembali.

Penyimpanan:

Simpan di tempat terkunci.

Pembuangan:

Buang isi / wadah ke tempat pembuangan limbah yang disetujui.

Bahaya lain

Jangan dicampur dengan pemutih atau produk lain yang mengandung

klor - akan menyebabkan gas klorin.

BAGIAN 3. KOMPOSISI/INFORMASI TENTANG BAHAN PENYUSUN

Bahan/preparasi murni

Campuran

Nama kimia

No-CAS

Konsentrasi (%)

NATRIUM KARBONAT

497-19-8

30 - 60

Natrium perkarbonat

15630-89-4

10 - 30

NATRIUM METASILIKAT

6834-92-0

10 - 30

NATRIUM DODESILBENZENASULFONAT

25155-30-0

5 - 10

Fattyalcohol ethoxylates > 5EO

68551-12-2

1 - 5

BAGIAN 4. TINDAKAN PERTOLONGAN PERTAMA PADA KECELAKAAN

Jika kontak dengan mata

Basuhlah segera dengan banyak air, dan berikan air sebanyak-

banyaknya di bawah kelopak mata, sekurangnya selama 15 menit.

Lepas lensa kontak, jika digunakan dan mudah melakukannya.

Lanjutkan membilas. Segera panggil dokter.

Jika kontak dengan kulit

Segera cuci bersih dengan banyak air sedikitnya selama 15 menit.

Gunakan sabun lunak bila tersedia. Cuci pakaian yang tercemar

sebelum dipakai lagi. Cucilah sebersih mungkin sepatu sebelum

dipakai lagi. Segera panggil dokter.

Jika tertelan

Berkumurlah dengan air. JANGAN pancing supaya muntah. Jangan

sekali-kali memberikan apa pun lewat mulut kepada orang yang tidak

sadar. Segera panggil dokter.

Jika terhirup

Pindahkan ke tempat berudara segar. Tangani menurut gejala.

Tangani secara medis jika muncul gejala.

Perlindungan aiders pertama

Bila ada bahaya kontaminasi lihat bab 8 tentang perlengkapan

melindungi diri.

Instruksi kepada dokter

Tangani menurut gejala.

Gejala dan efek yang paling

penting, baik yang akut

maupun yang tertunda

Lihat bagian 11 untuk informasi yang lebih terperinci mengenai

berbagai efek dan gejala pada kesehatan.

BAGIAN 5. TINDAKAN PEMADAMAN KEBAKARAN

Media pemadam yang sesuai

Gunakan tindakan pemadaman kebakaran yang sesuai untuk situasi

lokal dan lingkungan sekitar.

Zat pemadam kebakaran

yang tidak sesuai

Tidak ada yang diketahui.

Bahaya spesifik yang

Eksposur terhadap produk-produk dekomposisi dapat berbahaya bagi

LEMBARAN DATA KESELAMATAN BAHAN

ECO-BRITE 150 DETERGENT

913315

3 / 8

diakibatkan bahan kimia

tersebut

kesehatan.

Produk pembakaran

berbahaya

Hasil penguraian mungkin termasuk bahan-bahan berikut:

Karbon oksida

Alat pelindung khusus bagi

petugas pemadam

kebakaran

Jika terjadi kebakaran, pakai SCBA (alat pernafasan swa-lengkap)

berpenutup wajah bertekanan-positif dan pakaian pelindung.

Metode pemadaman khusus

Kumpulkan air bekas pemadam kebakaran yang tercemar secara

terpisah. Air ini tidak boleh dibuang ke saluran pembuangan. Residu

kebakaran dan air bekas pemadam kebakaran yang tercemar harus

dibuang sesuai dengan peraturan lokal. Jika terjadi kebakaran

dan/atau ledakan, jangan menghirup asap.

BAGIAN 6. TINDAKAN PENANGGULANGAN JIKA TERJADI TUMPAHAN DAN KEBOCORAN

Tindakan pencegahan

pribadi, peralatan pelindung

dan prosedur darurat

Pastikan ventilasi memadai. Jauhkan orang dari tumpahan/bocoran ke

arah yang berlawanan dengan arah angin. Hindari penghirupan,

penelanan dan kontak langsung dengan kulit dan mata. Jika karyawan

menghadapi konsentrasi yang melebihi ambang batas pajanan,

mereka harus memakai alat bantu pernapasan yang memenuhi

standar. Pastikan agar pembersihan dilakukan hanya oleh petugas

terlatih. Mengaculah pada langkah-langkah perlindungan yang

dicantumkan dalam seksi 7 dan 8.

Tindakan pencegahan untuk

melindungi lingkungan

Jangan sampai mengenai tanah, air permukaan atau air tanah.

Metode dan bahan untuk

penyimpanan dan

pembersihan

Sapulah dan sekoplah ke dalam wadah yang sesuai untuk dibuang.

BAGIAN 7. PENANGANAN DAN PENYIMPANAN

saran penanganan yang

aman

Jangan dimakan. Jangan menghirup

debu/asap/gas/kabut/uap/semburan. Gunakan hanya dengan ventilasi

yang cukup. Cucilah tangan bersih-bersih setelah menangani. Jangan

terkena mata, kulit atau pakaian. Jangan dicampur dengan pemutih

atau produk lain yang mengandung klor - akan menyebabkan gas

klorin.

Kondisi untuk penyimpanan

yang aman

Jauhkan dari jangkauan anak-anak. Jaga wadah tertutup rapat.

Simpan dalam wadah yang berlabel sesuai.

Suhu penyimpanan

0 °C ke 25 °C

BAGIAN 8. KONTROL PAPARAN/ PERLINDUNGAN DIRI

Komponen dengan parameter pengendalian di tempat kerja

Tidak mengandung bahan-bahan yang mempunyai nilai batas eksposur pekerjaan.

Pengendalian teknik yang

sesuai

Sistem ventilasi pembuangan yang efektif. Jaga konsentrasi udara di

bawah standar paparan okupasional.

Alat Pelindung Diri

LEMBARAN DATA KESELAMATAN BAHAN

ECO-BRITE 150 DETERGENT

913315

4 / 8

Perlindungan mata

Katamata pelindung keamanan

Topeng-wajah

Perlindungan tangan

Kenakan perlengkapan perlindungan pribadi berikut ini:

Jenis sarung tangan standar.

Sarung tangan kedap-air

Sarung tangan harus dibuang atau diganti apabila terdapat indikasi

mengalami degradasi atau kebocoran kimia.

Perlindungan kulit

Peralatan pelindung personal terdiri atas: sarung tangan pelindung,

kacamata keselamatan kerja dan baju pelindung

celemek tahan bahan kimia

Perlindungan pernapasan

Jika karyawan menghadapi konsentrasi yang melebihi ambang batas

pajanan, mereka harus memakai alat bantu pernapasan yang

memenuhi standar.

Tindakan higienis

Tangani sesuai dengan praktik kebersihan dan keselamatan industri

yang baik. Lepaskan dan cuci pakaian yang tercemar sebelum dipakai

lagi. Cuci muka, tangan dan kulit yang terpapar dengan seksama

setelah menangani. Menyediakan fasilitas untuk cepat membasahi

atau pembilasan pada mata dan tubuh pada kasus kontak atau

bahaya lain.

BAGIAN 9. SIFAT FISIKA DAN KIMIA

Tampilan

: serbuk

Warna

: putih, bening

: Parfum, Minyak wangi

11.1 - 11.5, 1 %

Titik nyala

Tidak berlaku.

Ambang Bau

Data tidak tersedia

Titik lebur/titik beku

Data tidak tersedia

Titik didih awal/rentang didih

> 100 °C

Laju penguapan

Data tidak tersedia

Flamabilitas (padatan, gas)

Data tidak tersedia

Tertinggi batas ledakan

Data tidak tersedia

Terendah batas ledakan

Data tidak tersedia

Tekanan uap

Data tidak tersedia

Kerapatan (densitas) uap

relatif

Data tidak tersedia

Berat jenis relatif

Data tidak tersedia

Kelarutan dalam air

larut

Kelarutan dalam pelarut lain

Data tidak tersedia

Koefisien partisi (n-

oktanol/air)

Data tidak tersedia

Suhu dapat membakar

sendiri (auto-ignition

temperature)

Data tidak tersedia

LEMBARAN DATA KESELAMATAN BAHAN

ECO-BRITE 150 DETERGENT

913315

5 / 8

Dekomposisi termal

Data tidak tersedia

Viskositas, kinematis

Data tidak tersedia

Sifat peledak

Data tidak tersedia

Sifat oksidator

Data tidak tersedia

Berat Molekul

Data tidak tersedia

Data tidak tersedia

BAGIAN 10. STABILITAS DAN REAKTIFITAS

Stabilitas kimia

Stabil pada kondisi normal.

Kemungkinan reaksi

berbahaya

Jangan dicampur dengan pemutih atau produk lain yang mengandung

klor - akan menyebabkan gas klorin.

Kondisi yang harus dihindari

Tidak ada yang diketahui.

Bahan non-kompatibel

Asam

Logam

Bahan organik

Produk berbahaya hasil

peruraian

Hasil penguraian mungkin termasuk bahan-bahan berikut:

Karbon oksida

BAGIAN 11. INFORMASI TOKSIKOLOGI

Informasi tentang rute

paparan

Penghirupan, Kena mata, Kena kulit

Kemungkinan Dampak Kesehatan

Mata

Menyebabkan kerusakan mata yang serius.

Kulit

Menimbulkan sensasi terbakar yang parah pada kulit.

Tertelan

Berbahaya jika tertelan. Menyebabkan sensasi terbakar pada saluran

pencernaan.

Penghirupan

Dapat menyebabkan iritasi pada hidung, tenggorokan, dan paru-paru.

Eksposur Kronis

Gangguan kesehatan tidak diketahui atau tidak diperkirakan jika

penggunaannya normal.

Pengalaman dengan paparan pada manusia

Kena mata

Kemerahan, Nyeri, Korosi

Kena kulit

Kemerahan, Nyeri, Korosi

Tertelan

Korosi, Sakit perut

Penghirupan

Iritasi alat pernafasan, Batuk

Toksisitas

Produk

LEMBARAN DATA KESELAMATAN BAHAN

ECO-BRITE 150 DETERGENT

913315

6 / 8

Toksisitas oral akut

: Perkiraan toksisitas akut : 1,402 mg/kg

Perkiraan toksisitas akut : 1,829 mg/kg

Toksisitas inhalasi akut

: Data tidak tersedia

Toksisitas kulit akut

: Perkiraan toksisitas akut : > 5,000 mg/kg

Kerusakan/gangguan kulit

Data tidak tersedia

Gangguan mata/kerusakan

mata serius

Data tidak tersedia

Sensitisasi sistem

pernafasan atau kulit

Data tidak tersedia

Karsinogenisitas

Data tidak tersedia

Pengaruh pada alat

reproduksi

Data tidak tersedia

Mutagenitas sel germinal

Data tidak tersedia

Teratogenisitas

Data tidak tersedia

STOT - paparan tunggal

Data tidak tersedia

STOT - paparan berulang

Data tidak tersedia

Derajat keracunan melalui

pernapasan

Data tidak tersedia

BAGIAN 12. INFORMASI EKOLOGI

Derajat racun bagi lingkungan (ekotoksisitas)

Dampak lingkungan

Toksik pada kehidupan perairan.

Produk

Keracunan untuk ikan

: Data tidak tersedia

Derajat racun bagi daphnia

dan binatang tak bertulang

belakang lainnya yang hidup

dalam air.

: Data tidak tersedia

Keracunan untuk ganggang

: Data tidak tersedia

Komponen

Keracunan untuk ikan

: NATRIUM KARBONAT

96 h LC50 Lepomis macrochirus (Ikan bluegill sunfish): 300 mg/l

NATRIUM METASILIKAT

96 h LC50 Ikan: 210 mg/l

NATRIUM DODESILBENZENASULFONAT

96 h LC50: 3.2 mg/l

Fattyalcohol ethoxylates > 5EO

96 h LC50 Ikan: 1.5 mg/l

Komponen

Derajat racun bagi daphnia

dan binatang tak bertulang

belakang lainnya yang hidup

dalam air.

: NATRIUM KARBONAT

48 h EC50 Ceriodaphnia (kutu air): 213.5 mg/l

LEMBARAN DATA KESELAMATAN BAHAN

ECO-BRITE 150 DETERGENT

913315

7 / 8

Natrium perkarbonat

48 h EC50 Daphnia (Kutu air): 4.9 mg/l

Ketahanan dan tingkat penguraian

Data tidak tersedia

Potensi penumpukan biologis

Data tidak tersedia

Mobilitas di dalam tanah

Data tidak tersedia

Dampak merugikan lainnya

Data tidak tersedia

BAGIAN 13. PERTIMBANGAN PEMBUANGAN/ PEMUSNAHAN

Metode pembuangan

Jika mungkin, pendauran-ulang lebih disukai daripada pembuangan

atau pembakaran. Jika proses daur-ulang tidak praktis, buang sesuai

dengan peraturan lokal. Buanglah sampah dalam fasilitas

pembuangan sampah yang disetujui.

Produk tidak boleh sampai memasuki saluran pembuangan, sungai,

danau dsb. atau tanah.

Pembuangan limbah

Buang sebagai produk yang tidak digunakan. Wadah kosong harus

dibawa ke tempat penanganan limbah yang telah disetujui untuk

didaur-ulang atau dibuang. Dilarang menggunakan kembali

kemasan/wadah yang sudah kosong. Buanglah sesuai dengan

peraturan lokal, negara bagian, dan federal.

BAGIAN 14. INFORMASI PENGANGKUTAN

Pengangkut/ pengirim barang/ pengirim bertanggung jawab untuk memastikan kemasan, label, dan

penandaan yang sesuai dengan jenis transportasi yang digunakan.

Transpor jalan

Nomor UN

3262

deskripsi barang

CORROSIVE SOLID, BASIC, INORGANIC, N.O.S.

(sodium metasilicate, sodium carbonate)

Kelas

Kelompok pengemasan

Berbahaya bagi lingkungan

Tidak

Transpor laut (IMDG/IMO)

Nomor UN

3262

deskripsi barang

CORROSIVE SOLID, BASIC, INORGANIC, N.O.S.

(NATRIUM METASILIKAT, sodium carbonate)

Kelas

Kelompok pengemasan

Bahan pencemar laut

Tidak

BAGIAN 15. INFORMASI YANG BERKAITAN DENGAN REGULASI

Regulasi domestik

LEMBARAN DATA KESELAMATAN BAHAN

ECO-BRITE 150 DETERGENT

913315

8 / 8

Sistem Harmonisasi Global Klasifikasi dan Label Pada Bahan Kimia (87/M-IND/PER/9/2009)

Komponen-komponen produk ini dilaporkan dalam inventorisasi berikut:

Inventaris TSCA Amerika Serikat :

belum ditentukan

Daftar Senyawa Domestik Kanada :

Produk ini mengandung komponen-komponen berikut yang terdaftar pada daftar NDSL Kanada.

Komponen-komponen lainnya terdapat pada daftar DSL Kanada.

Australia. Undang-undang (Pengkajian dan Pemberitahuan) Kimia Industri :

belum ditentukan

Selandia Baru. Inventaris Bahan Kimia (NZIoC), seperti yang diterbitkan oleh ERMA Selandia

Baru :

belum ditentukan

Jepang. ENCS - Inventaris Senyawa Kimia Yang Sudah Ada Dan Yang Baru :

belum ditentukan

Jepang. ISHL - Inventaris Senyawa Kimia (METI) :

belum ditentukan

Korea. Inventaris Bahan Kimia Yang Sudah Ada (KECI) :

belum ditentukan

Inventaris Bahan Kimia dan Senyawa Kimia Filipina (PICCS) :

Sesuai dengan inventaris

Cina. Inventaris Senyawa Kimia yang Sudah Ada :

Sesuai dengan inventaris

BAGIAN 16. INFORMASI LAIN

Tanggal penerbitan pertama

28.07.2016

Versi

Disiapkan oleh

Urusan peraturan

Perbahan-perubahan peraturan atau informasi kesehatan yang signifikan dalam revisi ini ditunjukkan

oleh batang di bagian sisi kiri MSDS.

Informasi yang diberikan dalam Lembar Data Keselamatan ini benar menurut pengetahuan, informasi,

dan keyakinan kami pada tanggal penerbitan. Informasi yang diberikan dimaksudkan hanya sebagai

pedoman untuk penanganan, penggunaan, pemprosesan, penyimpanan, pengangkutan,

pembuangan, dan pembebasan yang aman dan tidak boleh dianggap sebagai jaminan atau

spesifikasi mutu. Informasi hanya menyangkut bahan spesifik yang telah ditentukan dan dapat tidak

berlaku jika bahan tersebut digunakan sebagai campuran dengan bahan lain atau dalam proses lain

kecuali jika dinyatakan secara spesifik dalam tulisan.

8-2-2019

Bee protection: ANSES makes recommendations to strengthen the regulatory framework

Bee protection: ANSES makes recommendations to strengthen the regulatory framework

As part of the Government's action plan on plant protection products and reduced dependence on pesticides in agriculture, ANSES is today publishing the results of its expert appraisal and its recommendations to strengthen the regulatory framework for the protection of bees and other pollinating insects. The aim of these recommendations is to further reduce bee exposure to plant protection products.

France - Agence Nationale du Médicament Vétérinaire

5-2-2019

Evaluation of confirmatory data following the Article 12 MRL review for spinosad

Evaluation of confirmatory data following the Article 12 MRL review for spinosad

Published on: Mon, 04 Feb 2019 The applicant Dow AgroSciences Ltd submitted a request to the competent national authority in the Netherlands to evaluate the confirmatory data that were identified for spinosad in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. The data gaps related to residue trials on globe artichokes, flowering brassica and the nature of residues in processed commodities were satisfactorily addressed. A new feedi...

Europe - EFSA - European Food Safety Authority EFSA Journal

4-2-2019

Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling

Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that it’s wholly owned subsidiary, Dr Reddy’s Laboratories, Inc is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetram in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags to the hospital level in U.S.A.

FDA - U.S. Food and Drug Administration

2-2-2019

Evaluation of confirmatory data following the Article 12 MRL review for imazamox

Evaluation of confirmatory data following the Article 12 MRL review for imazamox

Published on: Fri, 01 Feb 2019 The applicant BASF SE submitted a request to the competent national authority in France to evaluate the confirmatory data that were identified for imazamox in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, the applicant submitted new residue trials on rice. Since the number of trials was not sufficient, the data gap was considered only partially addressed. The remaining dat...

Europe - EFSA - European Food Safety Authority EFSA Journal

1-2-2019

Safety of concentrated l‐lysine (base), l‐lysine monohydrochloride and l‐lysine sulfate produced using different strains of Corynebacterium glutamicum for all animal species based on a dossier submitted by FEFANA asbl

Safety of concentrated l‐lysine (base), l‐lysine monohydrochloride and l‐lysine sulfate produced using different strains of Corynebacterium glutamicum for all animal species based on a dossier submitted by FEFANA asbl

Published on: Thu, 31 Jan 2019 The EFSA FEEDAP Panel previously (2016) could not conclude on the safety of certain concentrated liquid l‐lysine (base), l‐lysine monohydrochloride (HCl) and l‐lysine sulfate products manufactured using different strains of Corynebacterium glutamicum. New information on the safety of these products was provided by the applicant. The recipient strain C. glutamicum KCTC 12307BP qualifies for qualified presumption of safety (QPS) approach for safety assessment, the genetic mo...

Europe - EFSA - European Food Safety Authority EFSA Journal

25-1-2019

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 9: suitability of taxonomic units notified to EFSA until September 2018

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 9: suitability of taxonomic units notified to EFSA until September 2018

Published on: Thu, 24 Jan 2019 The qualified presumption of safety (QPS) procedure was developed to provide a harmonised generic pre‐evaluation to support safety risk assessments of biological agents performed by EFSA's Scientific Panels. The taxonomic identity, body of knowledge, safety concerns and antimicrobial resistance were assessed. Safety concerns identified for a taxonomic unit are, where possible and reasonable in number, reflected by ‘qualifications’ which should be assessed at the strain lev...

Europe - EFSA - European Food Safety Authority EFSA Journal

23-1-2019

ANSES recommends improving baby diaper safety

ANSES recommends improving baby diaper safety

Today, ANSES published its assessment of the risks of chemicals found in baby diapers. Based on tests conducted on disposable diapers and their use, the Agency’s assessment highlighted several chemicals for which safety threshold values were exceeded. With regard to the possible risks of these chemicals to baby health, ANSES recommends eliminating these latter or reducing their levels as much as possible in disposable diapers.

France - Agence Nationale du Médicament Vétérinaire

22-1-2019

Modification of the existing maximum residue levels for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds

Modification of the existing maximum residue levels for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Isagro S.p.A submitted a request to the competent national authority in Italy to modify the existing maximum residue levels (MRLs) for the active substance tetraconazole in various crops and animal commodities. The data submitted in support of the request were found to be sufficient to derive MRL proposals for tetraconazole in kaki/Japanese persimmon, linseeds and poppy seeds. Adequate analytical me...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Assessment of genetically modified maize MON 89034 × 1507 × NK603 × DAS‐40278‐9 and subcombinations independently of their origin for food and feed uses, import and processing, under Regulation (EC) No 1829‐2003 (application EFSA‐GMO‐NL‐2013‐112)

Assessment of genetically modified maize MON 89034 × 1507 × NK603 × DAS‐40278‐9 and subcombinations independently of their origin for food and feed uses, import and processing, under Regulation (EC) No 1829‐2003 (application EFSA‐GMO‐NL‐2013‐112)

Published on: Wed, 16 Jan 2019 Maize MON 89034 × 1507 × NK603 × DAS‐40278‐9 (four‐event stack maize) was produced by conventional crossing to combine four single events: MON 89034, 1507, NK603 and DAS‐40278‐9. The GMO Panel previously assessed the four single events and four of their subcombinations and did not identify safety concerns. No new data on the maize single events or their four subcombinations that could lead to modification of the original conclusions on their safety have been identified. Th...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Genotoxicity assessment of chemical mixtures

Genotoxicity assessment of chemical mixtures

Published on: Wed, 16 Jan 2019 This document provides guidance for communicators on how to communicate the various expressions of uncertainty described in EFSA's document: ‘Guidance on uncertainty analysis in scientific assessments’. It also contains specific guidance for assessors on how best to report the various expressions of uncertainty. The document provides a template for identifying expressions of uncertainty in scientific assessments and locating the specific guidance for each expression. The g...

Europe - EFSA - European Food Safety Authority EFSA Journal

17-1-2019

Guidance on Communication of Uncertainty in Scientific Assessments

Guidance on Communication of Uncertainty in Scientific Assessments

Published on: Wed, 16 Jan 2019 This document provides guidance for communicators on how to communicate the various expressions of uncertainty described in EFSA's document: ‘Guidance on uncertainty analysis in scientific assessments’. It also contains specific guidance for assessors on how best to report the various expressions of uncertainty. The document provides a template for identifying expressions of uncertainty in scientific assessments and locating the specific guidance for each expression. The g...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Safety and efficacy of B‐Act® (Bacillus licheniformis DSM 28710) as a feed additive for turkeys for fattening, turkeys reared for breeding and minor poultry species for fattening or raised for laying

Safety and efficacy of B‐Act® (Bacillus licheniformis DSM 28710) as a feed additive for turkeys for fattening, turkeys reared for breeding and minor poultry species for fattening or raised for laying

Published on: Mon, 14 Jan 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed was asked to deliver a scientific opinion on the safety and efficacy of B‐Act® when used in feed for turkeys for fattening, reared for breeding and minor poultry species for fattening or raised for laying. B‐Act® is a preparation containing viable spores of a Bacillus licheniformis strain. This species is considered by EFSA to be suitable for the qua...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Software for Benchmark Dose Modelling

Software for Benchmark Dose Modelling

Published on: Mon, 14 Jan 2019 In specific contract No 7 issued under the framework agreement OC/EFSA/AMU/2015/02, EFSA requested Open Analytics to extend the Web application for Benchmark Dose Modelling built under specific contracts No 3 and No 4. The Web application is further developed in R with focus on creating a graphical module to evaluate model fit and to modify specific plot settings, as specified in the Technical Annex to Specific Contract No 7. The web application includes the latest develop...

Europe - EFSA - European Food Safety Authority EFSA Journal

15-1-2019

Assessment of genetically modified maize MON 89034 × 1507 × MON 88017 × 59122 × DAS‐40278‐9 and subcombinations independently of their origin for food and feed uses, import and processing under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐NL‐2013‐11

Assessment of genetically modified maize MON 89034 × 1507 × MON 88017 × 59122 × DAS‐40278‐9 and subcombinations independently of their origin for food and feed uses, import and processing under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐NL‐2013‐11

Published on: Mon, 14 Jan 2019 Maize MON 89034 × 1507 × MON 88017 × 59122 × DAS‐40278‐9 (five‐event stack maize) was produced by conventional crossing to combine five single events: MON 89034, 1507, MON 88017, 59122 and DAS‐40278‐9. The GMO Panel previously assessed the 5 single maize events and 11 of their subcombinations and did not identify safety concerns. No new data on the single maize events or their 11 subcombinations that could modify the original conclusions on their safety were identified. Th...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Published on: Fri, 11 Jan 2019 The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the application for renewal of authorisation of organic form of selenium produced by Saccharomyces cerevisiae NCYC R397 (Alkosel®) for all animal species. The FEEDAP Panel has delivered two opinions (on 2007 and 2016) on the safety and efficacy of the additive. The additive is characterised as organic selenium mainly selenomethionine (63%); it was ini...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Safety and efficacy of HOSTAZYM® X (endo‐1,4‐beta‐xylanase) as a feed additive for rabbits for fattening

Safety and efficacy of HOSTAZYM® X (endo‐1,4‐beta‐xylanase) as a feed additive for rabbits for fattening

Published on: Fri, 11 Jan 2019 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of HOSTAZYM® X as a feed additive for rabbits for fattening. HOSTAZYM® X contains endo‐1,4‐beta‐xylanase produced by a strain of Trichoderma citrinoviride and is available in liquid and solid formulations. It is authorised as a feed additive for chickens for fattening, turkeys f...

Europe - EFSA - European Food Safety Authority EFSA Journal

10-1-2019

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Published on: Wed, 09 Jan 2019 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with a genetically modified strain of Trichoderma reesei by Danisco US Inc. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organic solids (TOS) are removed by distill...

Europe - EFSA - European Food Safety Authority EFSA Journal

8-1-2019

Monitoring sales of veterinary antimicrobials

Monitoring sales of veterinary antimicrobials

Veterinary antimicrobial sales have been monitored annually by the Agency since 1999. This monitoring is based on the recommendations in Chapter 6.8 of the OIE's 2016 Terrestrial Animal Health Code "Monitoring of the quantities and usage patterns of antimicrobial agents used in food-producing animals".

France - Agence Nationale du Médicament Vétérinaire

22-12-2018

Modification of the existing maximum residue level for captan in hops

Modification of the existing maximum residue level for captan in hops

Published on: Fri, 21 Dec 2018 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant ADAMA Agriculture BV on behalf of ADAMA Makhteshim Ltd. submitted a request to the competent national authority in the Netherlands to modify the existing maximum residue level for the active substance captan in hops. The data submitted in support of the request were found to be insufficient to conclude whether the existing residue definitions are appropriate for hops. Although the number of residue ...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-12-2018

One lot of Equate brand Lens Care System and Multi-Purpose Solution voluntarily recalled because of a labelling error

One lot of Equate brand Lens Care System and Multi-Purpose Solution voluntarily recalled because of a labelling error

Teva Canada is voluntarily recalling one lot (Lot 150261) of two products because of a labelling error. While the outer carton of Equate brand Lens Care System is correctly labelled, the bottle within the carton is mislabelled as Equate brand Multi-Purpose Solution. Because of the labelling error, the company is recalling both products labelled with Lot 150261. Bottles labelled as Equate Multi-Purpose Solution should contain a 0.0001% w/v polyhexanide based disinfecting solution for rinsing. The mislabel...

Health Canada

14-12-2018

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...

Europe - EFSA - European Food Safety Authority Publications

13-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce <i>E. coli</i> O157:H7 outbreak investigation

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce <i>E. coli</i> O157:H7 outbreak investigation

Statement from FDA Commissioner Scott Gottlieb, M.D. and FDA Deputy Commissioner Frank Yiannas on new findings and updated consumer recommendations related to the romaine lettuce E. coli O157:H7 outbreak investigation

FDA - U.S. Food and Drug Administration

12-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to improve drug quality through vigilant oversight of data integrity and good manufacturing practice

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to improve drug quality through vigilant oversight of data integrity and good manufacturing practice

FDA releases guidance with recommendations for drug manufacturers regarding good manufacturing practices and data integrity

FDA - U.S. Food and Drug Administration

6-2-2019

Today, the @US_FDA issued a Letter to Healthcare Providers about diagnosing and treating BIA-ALCL. Click to read more about the #FDA's recommendations:  https://go.usa.gov/xENj4  #MedicalDevicepic.twitter.com/szwLQ8FvxA

Today, the @US_FDA issued a Letter to Healthcare Providers about diagnosing and treating BIA-ALCL. Click to read more about the #FDA's recommendations: https://go.usa.gov/xENj4  #MedicalDevicepic.twitter.com/szwLQ8FvxA

Today, the @US_FDA issued a Letter to Healthcare Providers about diagnosing and treating BIA-ALCL. Click to read more about the #FDA's recommendations: https://go.usa.gov/xENj4  #MedicalDevice pic.twitter.com/szwLQ8FvxA

FDA - U.S. Food and Drug Administration

31-1-2019

Today @US_FDA issued a safety communication to providers and patients  about the risks of air-in-line when using infusion pumps, rapid  infusers, and fluid warmers. Find out more about the risks and #FDA  recommendations:  https://go.usa.gov/xE9g7  ##Medi

Today @US_FDA issued a safety communication to providers and patients about the risks of air-in-line when using infusion pumps, rapid infusers, and fluid warmers. Find out more about the risks and #FDA recommendations: https://go.usa.gov/xE9g7  ##Medi

Today @US_FDA issued a safety communication to providers and patients about the risks of air-in-line when using infusion pumps, rapid infusers, and fluid warmers. Find out more about the risks and #FDA recommendations: https://go.usa.gov/xE9g7  # #MedicalDevice pic.twitter.com/lLIyoG6680

FDA - U.S. Food and Drug Administration

16-1-2019

EU/3/13/1150 (AstraZeneca AB)

EU/3/13/1150 (AstraZeneca AB)

EU/3/13/1150 (Active substance: Moxetumomab pasudotox) - Transfer of orphan designation - Commission Decision (2019)230 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002544

Europe -DG Health and Food Safety

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins, decision type: , therapeutic area: , PIP number: P/0338/2018

Opinion/decision on a Paediatric investigation plan (PIP): Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins, decision type: , therapeutic area: , PIP number: P/0338/2018

Opinion/decision on a Paediatric investigation plan (PIP): Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins, decision type: , therapeutic area: , PIP number: P/0338/2018

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized mRNA that will be translated to functional human cystic fibrosis transmembrane conductance regulator protein after cellular uptake

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes

Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes

Scientific recommendation on classification of advanced therapy medicines: Allogeneic Epstein-Barr Virus specific cytotoxic T lymphocytes

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Scientific recommendation on classification of advanced therapy medicines: In vitro cultured autologous mesenchymal stem cells isolated from bone marrow

Europe - EMA - European Medicines Agency

7-1-2019


Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated virus serotype 9 vector encoding the soluble lysosomal enzyme TPP1

Europe - EMA - European Medicines Agency

4-1-2019


New product information wording: extracts from PRAC recommendations on signals adopted at the 26-29 November 2018 PRAC

New product information wording: extracts from PRAC recommendations on signals adopted at the 26-29 November 2018 PRAC

New product information wording: extracts from PRAC recommendations on signals adopted at the 26-29 November 2018 PRAC

Europe - EMA - European Medicines Agency

19-12-2018


Recommendations on eligibility to PRIME scheme -  Adopted at the CHMP meeting of 10-13 December 2018

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 10-13 December 2018

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 10-13 December 2018

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow

Scientific recommendation on classification of advanced therapy medicinal products: Mesenchymal stem cells isolated from autologous bone marrow

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous melanocytes

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous muscle-derived stem cells

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes

Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes

Scientific recommendation on classification of advanced therapy medicinal products: Human autologous keratinocytes

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Viable human autologous skin fibroblasts

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes

Scientific recommendation on classification of advanced therapy medicinal products: In vitro cultured autologous chondrocytes

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured adipose derived mesenchymal stem cells

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Extracellular matrix isolated from adipose tissue

Scientific recommendation on classification of advanced therapy medicinal products: Extracellular matrix isolated from adipose tissue

Scientific recommendation on classification of advanced therapy medicinal products: Extracellular matrix isolated from adipose tissue

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured fibroblasts

Scientific recommendation on classification of advanced therapy medicinal products: Autologous cultured fibroblasts

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing prostate antigens

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing prostate antigens

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing prostate antigens

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin

Scientific recommendation on classification of advanced therapy medicinal products: Live-attenuated, double-deleted Listeria monocytogenes expressing human mesothelin

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)

Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)

Scientific recommendation on classification of advanced therapy medicinal products: Concentrate of autologous bone marrow-derived mononuclear cells (BM-MNC)

Europe - EMA - European Medicines Agency

18-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Allogenic bone marrow derived mesenchymal stem cells expanded in vitro

Scientific recommendation on classification of advanced therapy medicinal products: Allogenic bone marrow derived mesenchymal stem cells expanded in vitro

Scientific recommendation on classification of advanced therapy medicinal products: Allogenic bone marrow derived mesenchymal stem cells expanded in vitro

Europe - EMA - European Medicines Agency

18-12-2018

EU/3/18/2107 (MUCPharm Pty Ltd)

EU/3/18/2107 (MUCPharm Pty Ltd)

EU/3/18/2107 (Active substance: Acetylcysteine) - Orphan designation - Commission Decision (2018)9022 of Tue, 18 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/150/18

Europe -DG Health and Food Safety

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells - Tissue engineered product

Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells - Tissue engineered product

Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells - Tissue engineered product

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette

Scientific recommendation on classification of advanced therapy medicinal products: Recombinant adeno-associated viral vector capsid containing the human iduronate-2-sulfatase (hIDS) expression cassette

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid

Scientific recommendation on classification of advanced therapy medicinal products: Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of two normal allogeneic human myoblasts

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed patient-specific mRNA molecule encoding neo-epitopes that are specifically derived from tumour tissue

Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed patient-specific mRNA molecule encoding neo-epitopes that are specifically derived from tumour tissue

Scientific recommendation on classification of advanced therapy medicinal products: In vitro transcribed patient-specific mRNA molecule encoding neo-epitopes that are specifically derived from tumour tissue

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Four in vitro transcribed mRNA molecules each encoding one tumour antigen

Scientific recommendation on classification of advanced therapy medicinal products: Four in vitro transcribed mRNA molecules each encoding one tumour antigen

Scientific recommendation on classification of advanced therapy medicinal products: Four in vitro transcribed mRNA molecules each encoding one tumour antigen

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of defective myoblasts from a Duchenne Muscular Dystrophy patient with normal myoblasts

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of defective myoblasts from a Duchenne Muscular Dystrophy patient with normal myoblasts

Scientific recommendation on classification of advanced therapy medicinal products: Dystrophin expressing chimeric cells obtained by ex vivo fusion of defective myoblasts from a Duchenne Muscular Dystrophy patient with normal myoblasts

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous suspension of blood-derived endothelial and hematopoietic stem/progenitor cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous suspension of blood-derived endothelial and hematopoietic stem/progenitor cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous suspension of blood-derived endothelial and hematopoietic stem/progenitor cells

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous anti-BCMA (B-cell maturation antigen) chimeric antigen receptor (CAR) T-cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous anti-BCMA (B-cell maturation antigen) chimeric antigen receptor (CAR) T-cells

Scientific recommendation on classification of advanced therapy medicinal products: Autologous anti-BCMA (B-cell maturation antigen) chimeric antigen receptor (CAR) T-cells

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells

Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells

Scientific recommendation on classification of advanced therapy medicinal products: Homogenate of antlerogenic stem cells

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Non-replicating recombinant adeno-associated virus carrying a fragment of the Channelrhodopsin-2 (ChR2) protein

Scientific recommendation on classification of advanced therapy medicinal products: Non-replicating recombinant adeno-associated virus carrying a fragment of the Channelrhodopsin-2 (ChR2) protein

Scientific recommendation on classification of advanced therapy medicinal products: Non-replicating recombinant adeno-associated virus carrying a fragment of the Channelrhodopsin-2 (ChR2) protein

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Adeno-associated virus (AAV) vector encoding genes from an algae channel rhodopsin

Scientific recommendation on classification of advanced therapy medicinal products: Adeno-associated virus (AAV) vector encoding genes from an algae channel rhodopsin

Scientific recommendation on classification of advanced therapy medicinal products: Adeno-associated virus (AAV) vector encoding genes from an algae channel rhodopsin

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Four independent DNA plasmid vectors encoding HBV antigens and human interleukin-12

Scientific recommendation on classification of advanced therapy medicinal products: Four independent DNA plasmid vectors encoding HBV antigens and human interleukin-12

Scientific recommendation on classification of advanced therapy medicinal products: Four independent DNA plasmid vectors encoding HBV antigens and human interleukin-12

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Autologous fibroblasts expanded in vitro

Scientific recommendation on classification of advanced therapy medicinal products: Autologous fibroblasts expanded in vitro

Scientific recommendation on classification of advanced therapy medicinal products: Autologous fibroblasts expanded in vitro

Europe - EMA - European Medicines Agency

12-12-2018


Scientific recommendation on classification of advanced therapy medicinal products: Live attenuated Listeria monocytogenes transfected with plasmids encoding HPV fusion protein

Scientific recommendation on classification of advanced therapy medicinal products: Live attenuated Listeria monocytogenes transfected with plasmids encoding HPV fusion protein

Scientific recommendation on classification of advanced therapy medicinal products: Live attenuated Listeria monocytogenes transfected with plasmids encoding HPV fusion protein

Europe - EMA - European Medicines Agency